TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)

TELA Bio, Inc.

FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.
FY2024 net loss narrowed to $37.8M from $46.7M in 2023; Q4 net loss $9.2M vs $12.9M a year ago.
FY2025 revenue guidance $85-88M (23-27% growth); Q1 2025 revenue expected $17-18M (2-8% growth).
Operating expenses step down Q3 to Q4; management targets 2025 OpEx flat vs 2024.
OviTex IHR product for inguinal hernia repair launched mid-April 2024, sold over 1,200 units in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.